高露洁棕榄
CL
94.11
+1.44
+1.55%
高露洁棕榄
US · CL
#335 按市值排名
上市于 1970
94.11
+1.44
+1.55%
实时 - 追踪5344个代码 - 心跳于31秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
减持
- 最近一期(2026/Q3)披露持股的机构数量减少了6家。
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 85.90% -0.03pp
- 机构数量
- 2,347 -6
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份,同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后;资金流向数据为每日更新。请将其作为方向性的交叉验证参考,而非精确的择时信号。
持股人类型
Mutual Fund71.16%
Public Company4.90%
Hedge Fund2.80%
Government Pension Fund2.42%
Private Company2.29%
Sovereign Wealth Fund1.32%
Family Office/Trust0.30%
Insurance Company0.27%
Corporate Pension Plan0.18%
Other14.37%
主要股东 截至 2026-06-30
BlackRock
8.77% · 69.92M 股
Vanguard Capital Management, LLC
7.12% · 56.78M 股
State Street Global Advisors
5.90% · 47.02M 股
T. Rowe Price Group, Inc.
3.50% · 27.94M 股
Vanguard Portfolio Management, LLC
3.01% · 24.02M 股
Other
71.69%
Geode Capital Management, LLC
2.90% · 23.14M 股
Morgan Stanley
1.78% · 14.16M 股
BNY Mellon Asset Management
1.63% · 13.02M 股
Deutsche Asset & Wealth Management
1.45% · 11.53M 股
UBS Asset Management
1.33% · 10.56M 股
条形长度是相对于此处列出的最大股东而言,并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 32次买入 · 16次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Noel Wallace | Chairperson & CEO | 0.06% |
| Jennifer Daniels | Chief Legal Officer | 0.01% |
| Panagiotis Tsourapas | Group President of Europe & Developing Markets | 0.01% |
| Stanley Sutula | Chief Financial Officer | 0.01% |
| Prabha Parameswaran | Group President of Growth & Strategy | 0.01% |
| John Cahill | Independent Director | 0.00% |
| John Hazlin | President of Hill’s Pet Nutrition | 0.00% |
| Shane Grant | Chief Operating Officer of Americas | 0.00% |
| C. Harris | Independent Director | 0.00% |
| Betsy Fishbone | Executive VP and Sr Assoc of GC HR Lit Comp & NA Ops | 0.00% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-30 | Lorrie Norrington | Lead Independent Director | Other Acquisition | +300 | $87.42 |
| 2026-09-30 | John Paul Bilbrey | Independent Director | Other Acquisition | +271 | $87.42 |
| 2026-09-30 | Brian Newman | Director | Other Acquisition | +214 | $87.42 |
| 2026-09-15 | Noel Wallace | Chairperson & CEO | Other Acquisition | +29,649 | -- |
| 2026-09-15 | Noel Wallace | Chairperson & CEO | Other Derivative Acquisition | +205,197 | $87.02 |
| 2026-09-15 | Panagiotis Tsourapas | Group President of Europe & Developing Markets | Other Acquisition | +4,597 | -- |
| 2026-09-15 | Panagiotis Tsourapas | Group President of Europe & Developing Markets | Other Derivative Acquisition | +31,814 | $87.02 |
| 2026-09-15 | Stanley Sutula | Chief Financial Officer | Other Acquisition | +8,045 | -- |
| 2026-09-15 | Stanley Sutula | Chief Financial Officer | Other Derivative Acquisition | +55,674 | $87.02 |
| 2026-09-15 | Shane Grant | Chief Operating Officer of Americas | Other Acquisition | +7,355 | -- |
| 2026-09-15 | Shane Grant | Chief Operating Officer of Americas | Other Derivative Acquisition | +50,902 | $87.02 |
| 2026-09-15 | John Hazlin | President of Hill’s Pet Nutrition | Other Acquisition | +3,908 | -- |
| 2026-09-15 | John Hazlin | President of Hill’s Pet Nutrition | Other Derivative Acquisition | +27,042 | $87.02 |
| 2026-09-15 | Gregory Malcolm | Vice President | Other Acquisition | +1,081 | -- |
| 2026-09-15 | Gregory Malcolm | Vice President | Other Derivative Acquisition | +7,477 | $87.02 |
| 2026-09-15 | Sally Massey | Chief Human Resources Officer | Other Acquisition | +3,333 | -- |
| 2026-09-15 | Sally Massey | Chief Human Resources Officer | Other Derivative Acquisition | +23,065 | $87.02 |
| 2026-09-15 | Betsy Fishbone | Executive VP and Sr Assoc of GC HR Lit Comp & NA Ops | Other Acquisition | +2,207 | -- |
| 2026-09-15 | Betsy Fishbone | Executive VP and Sr Assoc of GC HR Lit Comp & NA Ops | Other Derivative Acquisition | +15,271 | $87.02 |
| 2026-09-12 | Noel Wallace | Chairperson & CEO | Sale to Issuer | -12,479 | $86.80 |
Form 4 申报记录,每家公司显示最新的一批。"Other Derivative Acquisition"(其他衍生品获取)类目多为限制性股票/期权归属,并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:30 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
高露洁棕榄 讨论区 0 条评论